Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Status:
Completed
Trial end date:
2018-06-26
Target enrollment:
Participant gender:
Summary
The primary objective is, first, the comparison of tamoxifen and anastrozole and, second, the
comparison of zoledronate added to standard adjuvant therapy with controls according to
disease-free survival (DFS) in premenopausal patients with non-metastatic breast cancer
treated with tamoxifen or anastrozole. To assess whether zoledronate added to standard
adjuvant therapy can decrease or even prevent bone loss in patients treated with hormonal
blockade combined with an antiestrogen or aromatase inhibitor.